Low rate of conversion to positive tuberculosis status among patients with psoriasis on biologic therapies: A retrospective study from a US academic medical center

Daniel, Vijaya T.; Blankenship, Kaitlin; Daly, Robert F.; Tkachenko, Elizabeth; Morss-Walton, Peyton C; Levin, Nikki A.

doi:10.1016/j.jaad.2020.09.075

Cited by 4 publications

(4 citation statements)

References 4 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Recently due to low rate of conversion to positive TB status among patients with psoriasis on biologic therapies, it is recommended that annual testing for LTBI only among high risk patients (eg, patients who live, work, or travel where TB exposure is likely) . 32 However, one of our patients's QFT result turned positive after 6 months of SEC treatment, indicating that more frequent screening for LTBI is required in QFT_patients in China.…”

Section: Discussionmentioning

confidence: 72%

Is chemoprophylaxis necessary for all latent tuberculosis infection patients receivingIL‐17 inhibitors? A cohort study

Shen

Zhang

Zhou

et al. 2020

Dermatologic Therapy

View full text Add to dashboard Cite

The tuberculosis (TB) burden is high in China, with a 32% prevalence of latent tuberculosis infection (LTBI) in Beijing. Screening for LTBI and the chemoprophylaxis of positive patients are recommended prior to biologic therapy. To evaluate the TBrelated safety of secukinumab (SEC) in a cohort of plaque psoriasis patients with LTBI receiving different treatments. Plaque psoriasis patients eligible for SEC treatment were screened for TB. LTBI patients (QuantiFeron-TB test positive, QFT+) receiving SEC were closely monitored by chest radiograph, ESR or hs-CRP, and blood counts every 12 to 20 weeks for active TB infection. QFT_patients receiving SEC treatment were screened for LTBI every 6 to 12 months. Of 42 patients treated with SEC, 19 were QFT+ (45.24%). A QFT_patient became QFT+ after 6 months treatment. Two patients started SEC treatment from 2015 to 2016 and were followed up 268 and 216 weeks later, respectively. Three patients received chemoprophylaxis, 17 did not because of safety concerns or being unable to complete the process. During the 16-to 268-week follow-up, no signs of TB reactivation were observed in the 20 LTBI patients receiving SEC. Plaque psoriasis patients with LTBI who received no chemoprophylaxis could be safely treated with SEC.

show abstract

Section: Discussionmentioning

confidence: 72%

Is chemoprophylaxis necessary for all latent tuberculosis infection patients receivingIL‐17 inhibitors? A cohort study

Shen

Zhang

Zhou

et al. 2020

Dermatologic Therapy

View full text Add to dashboard Cite

show abstract

“…A long-term single-center retrospective study in the USA, an area with low TB risk, reported 1 LTBI case per 428 patient-years and no active TB cases among patients using biologic agents, including TNFi, IL-17i, and IL-12/23i [ 3 ]. In Italy, another area with low TB risk, a 9-year retrospective study indicated a 6.50% QFT conversion rate with no reports of active TB among psoriasis patients after a median of 34-month biological treatment [ 4 ].…”

Section: Discussionmentioning

confidence: 99%

“…Biologic agents are pathogenesis-based therapeutic strategies that have revolutionized psoriasis treatment in the recent decades, and their use has grown widely because of efficacy and safety. However, there are still risks regarding their application in clinical practice [ 3 , 4 ]. In addition to common adverse effects such as upper tract infection and local injection reaction, tuberculosis (TB) infection remains a significant concern.…”

Section: Introductionmentioning

confidence: 99%

“…Recently, accumulating evidence based on real-world experience has illustrated the TB conversion rate among psoriasis patients treated with biologics in regions with low TB risk such as the USA and Italy. There are no reports of active TB, while the incidence of latent tuberculosis infection (LTBI) varies in these two regions [ 3 , 4 ]. Hence, the specific risk of LTBI or active TB among patients treated with biologics in different regions remains to be further explored.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

The Tuberculosis Positive Conversion Rate Among Psoriasis Patients Treated with Adalimumab and Secukinumab: A Single-Center Retrospective Study in China

Xiao

Chen

Zou

et al. 2022

Dermatol Ther (Heidelb)

View full text Add to dashboard Cite

Introduction The tuberculosis (TB) positive conversion rate among psoriasis patients who received biologics has been reported worldwide, particularly in regions with low TB risk. Nonetheless, the TB-related safety of biologics such as adalimumab and secukinumab remains elusive in areas with high TB risk. According to the World Tuberculosis Report 2021, China is the country with the second highest TB burden, but data on TB conversion are also limited. Thus, we performed a retrospective, single-center study to profile the TB infection status conversion ratio among psoriasis patients treated with adalimumab and secukinumab in China. Methods Patients were enrolled between April 2019 and February 2021 from West China Hospital, Sichuan University. Baseline and relevant clinical information were summarized, and proper statistical analysis was used under different conditions. Results Five (5.43%) patients suffered TB conversion in the adalimumab group, two of whom developed active TB within the first 6 months. In the secukinumab group, four (5.26%) patients had TB positive conversion with no reports of active TB. Conclusion Our data show a relatively high rate of TB conversion among these psoriasis patients after mean treatment duration of 17.13 months. We recommend that, in patients who receive adalimumab, TB be reevaluated after the first 3 months and then monitored semiannually for the next 2 years. For patients treated with secukinumab, annual examination is sufficient.

show abstract

Adalimumab/ustekinumab

2021

Reactions Weekly

View full text Add to dashboard Cite

Low rate of conversion to positive tuberculosis status among patients with psoriasis on biologic therapies: A retrospective study from a US academic medical center

Cited by 4 publications

References 4 publications

Is chemoprophylaxis necessary for all latent tuberculosis infection patients receivingIL‐17 inhibitors? A cohort study

Is chemoprophylaxis necessary for all latent tuberculosis infection patients receivingIL‐17 inhibitors? A cohort study

The Tuberculosis Positive Conversion Rate Among Psoriasis Patients Treated with Adalimumab and Secukinumab: A Single-Center Retrospective Study in China

Adalimumab/ustekinumab

Contact Info

Product

Resources

About